4th Familial Cancer Conference
Not eligible for ESCO credits
07.06.2010 - 08.06.2010
Madrid, Spain
CONFERENCE
Description
Chair: J. Benítez, ES - H. Vasen, NL
The 4th Familial | ![]() |
General information
ORGANISING SECRETARIAT
Ana Sofia Contreiras Cordeiro/Danielle Rouse
Centro Nacional de Investigaciones Oncológicas (CNIO) - Scientific Events
Melchor Fernández Almagro, 3
E-28029 Madrid - Spain
Tel: +34 91 224 6900
Fax: +34 91 224 6980
Email: meetings@cnio.es
ESO SECRETARIAT
Daniela Mengato
European School of Oncology
Via del Bollo 4
20123 Milan - Italy
Tel: +39 02 8546 4523
Fax: +39 02 8546 4545
Email: dmengato@eso.net
CONFERENCE VENUE
Centro Nacional de InvestigacionesOncológicas (CNIO)
Melchor Fernández Almagro, 3
E-28029 Madrid - Spain
OFFICIAL LANGUAGE
The official language of the conference will be English. No simultaneous translation will be provided.
CERTIFICATES
All participants will be issued with a certificate of attendance at the close of the conference.
The meeting has been appraised and approved by the Accreditation Council of Oncology in Europe (ACOE) acknowledging the quality of the scientific programme and its educational value. The event is accredited with 12 European CME credits.
BADGE
The badge is the only official evidence of registration and should be worn at all times during the conference. Loss of badge means loss of registration.
INSURANCE
The organisers bear no responsibility for untoward events in connection with, before, during and after the conference. Participants are strongly advised to take out their own personal and travel insurance coverage.
IMPORTANT DEADLINES
15/05/2010: poster abstracts deadline
15/05/2010: registration deadline (after this date, registration will only be available on-site)
15/05/2010: cancellation deadline
24/05/2010: replacement deadline
Faculty list
FACULTY
L. Aaltonen, University of Helsinki, FI
A. Antoniou, University of Cambridge, UK
J. Benítez, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
B. Bressac de Paillerets, Institute Gustave Roussy, Villejuif, FR
A. Castells, Hospital Clínic, Barcelona, ES
D. Goldgar, University of Utah, Salt Lake City, US
C. Guerra, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
C. Houdayer, Institut Curie, Paris, FR
Z. Kote-Jarai, The Institute of Cancer Research, Sutton, UK
F. Lalloo, St Mary’s Hospital, Manchester, UK
P. Lapunzina, Hospital La Paz, Madrid, ES
C. Lázaro, Institut Català d'Oncología, Barcelona, ES
J. Lubinski, Pomeranian Academy of Medicine, Szczecin, PL
E.R. Maher, University of Birmingham, UK
A. Osorio, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
J. Palacios, Hospitales Universitarios Virgendel Rocio, Sevilla, ES
P. Radice, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, IT
M. Robledo, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
S. Romeo, University of Las Palmas, Las Palmas de Gran Canaria, ES
S. Shanley, Royal Marsden Hospital, London, UK
D. Stoppa-Lyonet, Institut Curie, Paris, FR
J. Surralles, Universitat Autónoma de Barcelona, ES
S. Thorlacius, University of Turin, IT
I. Tomlinson, University of Oxford, UK
M. Urioste, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
H. Vasen, Leiden University Medical Centre,Leiden, NL
Programme
7 June
GENERAL CONCEPTS IN FAMILIAL CANCER | |
9:00 | Welcome |
9:10 | Genetic predisposition. Hereditary cancer syndromes |
9:30 | Familial cancer epidemiology |
9:50 | Genetic factors and cancer predisposition A. Antoniou, UK |
10:10 | Evaluation of unclassified variants |
10:30 | Group picture and coffee break. Poster discussion |
11:00 | Genetic counseling in familial cancer D. Stoppa-Lyonet, FR |
11:20 | Legal and ethical issues of genetic testing S. Romeo, ES |
11:40 | Round table |
HEREDITARY BREAST AND OVARIAN CANCER Chair: J. Lubinski, PL | |
12:00 | The family of breast cancer genes A. Osorio, ES |
12:20 | The pathology of BRCA1 and BRCA2 breast cancer J. Palacios, ES |
12:40 | Selection criteria and management choices in families at high genetic risk for breast/ovarian cancer F. Lalloo, UK |
13:00 | Early detection and new treatments for women at high risk S. Shanley, UK |
13:20 | Round table |
13:40 | Lunch break |
15:15 | Oral presentation from selected posters Chair: P. Radice, IT |
16:30 | Coffee break and poster discussion |
17:00 | Clinical cases Chair: H. Vasen, NL |
8 June
| COLORECTAL CANCER |
9:00 | Germinal genetic and epigenetic alterations in HNPCC |
9:20 | The genetic bases of FAP syndrome |
9:40 | Management of patients with FAP syndrome A. Castells, ES |
10:00 | Other CRC genes |
10:20 | Round table |
10:40 | Coffee break and poster discussion |
| OTHER INHERITED CANCER SYNDROMES Chair: L. Altonen, FI |
11:10 | New advances in Multiple Endocrine Neoplasia type 2 |
11:30 | The genetic portrait of familial melanoma B. Bressac de Paillerets, FR |
11:50 | Genetic complexity of neurofibromatosis 1 (NF1) C. Lázaro, ES |
12:10 | Clinical features and molecular genetics of VHL syndrome E.R. Maher, UK |
12:30 | Genetic and management of hereditary pancreatic syndromes H. Vasen, NL |
12:50 | Round table |
13:10 | Lunch break |
CANCER IN CHILDHOOD Chair: F. Lalloo, UK | |
14:45 | The Fanconi Anemia Syndrome J. Surralles, ES |
15:05 | The overgrowth syndromes and cancer predisposition P. Lapunzina, ES |
15:25 | Familial retinoblastoma (Rb). Genotype-phenotype correlations C. Houdayer, FR |
15:45 | Genetic Syndromes of the Ras/MAPK Pathway C. Guerra, ES |
16:05 | Round table |
16:25 | Coffee break and poster discussion |
NEW STRATEGIES IN THE SEARCH FOR CANCER GENES Chair: M. Robledo, ES | |
16:55 | Searching for high penetrance genes by linkage studies I. Tomlinson, UK |
17:15 | High throughput sequencing: Searching for cancer genes S. Thorlacius, IT |
17:35 | GWAS and prostate cancer Z. Kote-Jarai, UK |
17:55 | Round table |
Abstract
APPLICATION AND ABSTRACT SUBMISSION
You may apply and submit your abstract to the organising secretariat online at:
WWW.CNIO.ES/MEETINGS
Instructions for application and abstract submission
Participants with new data relevant to the subject of the conference may submit one abstract to be considered for poster presentation. Only papers whose abstracts have been reviewed and approved by the conference coordinators will be presented.
Abstracts should be written in English and the text should not exceed 2000 characters (or 450 words), title included.
The title should appear in capital letters.
For each author, type surname first, followed by first name and initials (presenting author incapital letters).
List of affiliations after the author's list.
Indicate 3-5 keywords at the end of the text.
The full address with telephone, fax number and email of the corresponding author must be provided. The corresponding author will receive all the subsequent communication concerning this abstract. Please also indicate your approval for publication in case the abstracts are issued in a journal.
Six posters will be selected for the oral presentation.
It is the responsibility of the presenting author to ascertain whether all authors are aware of the content of the abstract before submission.
THE POSTER ABSTRACTS DEADLINE IS PASSED (15 MAY 2010)